コンテンツへスキップ
Merck
  • Cardiomyocyte apoptosis contributes to pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated mice.

Cardiomyocyte apoptosis contributes to pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated mice.

Clinical science (London, England : 1979) (2014-04-10)
Soon Woo Nam, Hongqun Liu, Joe Z Wong, Annie Y Feng, Gavin Chu, Naeem Merchant, Samuel S Lee
要旨

Cirrhotic cardiomyopathy is defined as systolic and diastolic dysfunctions, electrophysiological changes and macroscopic structural changes. However, the underlying mechanisms of this syndrome remain unclear. A possible role of myocardial apoptosis in the pathogenesis has not been previously examined. We hypothesized that dysregulation of apoptotic signalling participates in cardiac dysfunction in the cirrhotic heart. Therefore, we evaluated apoptotic pathways in the hearts of mice with chronic BDL (bile duct ligation). A cirrhotic cardiomyopathy model was induced by BDL in mice. Left ventricular geometry and volumes were evaluated by MRI. Intrinsic and extrinsic apoptotic pathways were evaluated by immunohistochemical staining and Western blot analysis. Fas-mediated apoptosis was inhibited by in vivo administration of an anti-FasL (Fas ligand) monoclonal antibody, and subsequently cardiac contractility was measured in isolated cardiomyocytes. BDL-mice showed significantly more PARP [poly(ADP-ribose) polymerase] staining than sham controls (18.2±11.4 compared with 6.7±5.3; P<0.05). Fas protein expression and PARP cleavage were activated, whereas FLIP (Fas-associated death domain-like interleukin 1β-converting enzyme-inhibitory protein) was decreased compared with sham controls. The Bcl-2/Bax ratio was increased in BDL-mice compared with sham controls. Anti-FasL monoclonal antibody injection in BDL-mice improved systolic and diastolic dysfunctions in cardiomyocytes, but had no effect in sham controls. A net pro-apoptotic balance exists in BDL hearts, mainly mediated by activation of the extrinsic pathway, and abrogation of apoptosis improved contractility. These results suggest that apoptosis contributes to depressed cardiac contractility in a murine model of cirrhotic cardiomyopathy.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
メタノール, suitable for HPLC, ≥99.9%
Sigma-Aldrich
メタノール, ACS reagent, ≥99.8%
Sigma-Aldrich
メタノール, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
メタノール, HPLC Plus, ≥99.9%
Sigma-Aldrich
メタノール, suitable for HPLC, gradient grade, suitable as ACS-grade LC reagent, ≥99.9%
Sigma-Aldrich
メタノール, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8% (GC)
Sigma-Aldrich
メタノール, Laboratory Reagent, ≥99.6%
Sigma-Aldrich
メタノール, ACS spectrophotometric grade, ≥99.9%
Sigma-Aldrich
エチレンジアミン四酢酸 溶液, 0.02% in DPBS (0.5 mM), sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
メタノール, ACS reagent, ≥99.8%
Sigma-Aldrich
メタノール, BioReagent, ≥99.93%
Sigma-Aldrich
メタノール, Absolute - Acetone free
Sigma-Aldrich
エチレンジアミン四酢酸, anhydrous, crystalline, BioReagent, suitable for cell culture
Sigma-Aldrich
エチレンジアミン四酢酸, 99.995% trace metals basis
Sigma-Aldrich
メタノール, JIS special grade, ≥99.8%
USP
メチルアルコール, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
メタノール, ACS reagent, ≥99.8%
Sigma-Aldrich
メタノール, SAJ first grade, ≥99.5%
Sigma-Aldrich
メタノール, anhydrous, 99.8%
Sigma-Aldrich
エチレンジアミン四酢酸, ACS reagent, 99.4-100.6%, powder
Sigma-Aldrich
メタノール, puriss., meets analytical specification of Ph Eur, ≥99.7% (GC)
Sigma-Aldrich
メタノール, suitable for HPLC
Sigma-Aldrich
メタノール, SAJ special grade
Sigma-Aldrich
エチレンジアミン四酢酸, BioUltra, anhydrous, ≥99% (titration)
Sigma-Aldrich
エチレンジアミン四酢酸 二ナトリウム塩 溶液, BioUltra, for molecular biology, pH 8.0, ~0.5 M in H2O
Supelco
メタノール, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
メタノール, analytical standard
Sigma-Aldrich
メタノール, NMR reference standard
Sigma-Aldrich
エチレンジアミン四酢酸, purified grade, ≥98.5%, powder
Sigma-Aldrich
エチレンジアミン四酢酸, ≥98.0% (KT)